rEVO Biologics Announces Enrollment Of First Patient In Phase 3 Trial Of Atryn® To Treat Early Onset Preeclampsia (PRESERVE-1)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced the enrollment of the first patient in its Phase 3 clinical trial of ATryn® [antithrombin (Recombinant)], for the treatment of preeclampsia during the 24th to 28th week of pregnancy, or early onset preeclampsia. The objective of the PRESERVE-1 trial is to assess whether ATryn prolongs pregnancy in mothers with early onset preeclampsia, consequently reducing the high rates of neonatal mortality and disability caused by this condition.

Help employers find you! Check out all the jobs and post your resume.

Back to news